Ray currently works at Optum Rx within the Product & Strategy organization. Over the past 4 years he has been charged to explore the space of Pharmacogenomics, and how it could be utilized within the Pharmacy Benefit Manager space. In this work he has helped conduct 4 pilots and 1 clinical study. These studies have been targeted toward answering the companies killer questions. The last of which is what the clinical study was looking to answer, which is will the use of PGx drive down the total cost of care for a utilizing member. Ray has been at UnitedHealth Group for the better part of 15 years with roles Marketing, Research & Development, Operations, and Product Development.
Track 1, Day 3
While innovative precision technologies can improve patient outcomes; they present new information and price shocks to payers. Emerging clinical guidelines may add to the confusion and further hamper payer acceptance. During this session, we’ll explore payer perspectives in the evidence evaluation processes that guide coverage decisions.
Track 1, January 27
Mary Relling, St. Jude
Pharmacists have long recognized that using unique patient characteristics to guide pharmacotherapy decision-making can improve drug response and mitigate drug-associated risks. Age, weight, and dietary habits were among the first patient-specific characteristics used to individualize pharmacotherapy. As technologies advanced, analytic tools that measure surrogate markers of liver and renal function, together with drug concentrations in biological fluids, were adopted to optimize therapeutic regimens. Cutting-edge genomic technologies are now being integrated into patient care for the selection of targeted therapies and identification of those at increased risk of poor pharmacotherapy outcomes. We’re excited to bring together experts who are advancing pharmacogenomics at scale through cutting edge clinical implementation, research, and education.